JP2024102205A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2024102205A5 JP2024102205A5 JP2024074264A JP2024074264A JP2024102205A5 JP 2024102205 A5 JP2024102205 A5 JP 2024102205A5 JP 2024074264 A JP2024074264 A JP 2024074264A JP 2024074264 A JP2024074264 A JP 2024074264A JP 2024102205 A5 JP2024102205 A5 JP 2024102205A5
- Authority
- JP
- Japan
- Prior art keywords
- dose
- ifnar1
- inhibitor
- injection device
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163178739P | 2021-04-23 | 2021-04-23 | |
| US63/178,739 | 2021-04-23 | ||
| US202163245285P | 2021-09-17 | 2021-09-17 | |
| US63/245,285 | 2021-09-17 | ||
| US202163272851P | 2021-10-28 | 2021-10-28 | |
| US63/272,851 | 2021-10-28 | ||
| JP2023562678A JP7484027B2 (ja) | 2021-04-23 | 2022-04-21 | 皮下注射のための抗ｉｆｎａｒ１投薬計画 |
| PCT/EP2022/060592 WO2022223714A1 (en) | 2021-04-23 | 2022-04-21 | Anti-ifnar1 dosing regime for subcutaneous injection |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023562678A Division JP7484027B2 (ja) | 2021-04-23 | 2022-04-21 | 皮下注射のための抗ｉｆｎａｒ１投薬計画 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024102205A JP2024102205A (ja) | 2024-07-30 |
| JP2024102205A5 true JP2024102205A5 (enExample) | 2024-10-31 |
Family
ID=81750490
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023562678A Active JP7484027B2 (ja) | 2021-04-23 | 2022-04-21 | 皮下注射のための抗ｉｆｎａｒ１投薬計画 |
| JP2024074264A Pending JP2024102205A (ja) | 2021-04-23 | 2024-05-01 | 皮下注射のための抗ｉｆｎａｒ１投薬計画 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023562678A Active JP7484027B2 (ja) | 2021-04-23 | 2022-04-21 | 皮下注射のための抗ｉｆｎａｒ１投薬計画 |
Country Status (25)
| Country | Link |
|---|---|
| US (4) | US20220340669A1 (enExample) |
| EP (2) | EP4306541A3 (enExample) |
| JP (2) | JP7484027B2 (enExample) |
| KR (2) | KR20250092298A (enExample) |
| CN (2) | CN120392997A (enExample) |
| AU (2) | AU2022260531B2 (enExample) |
| BR (1) | BR112023021761A2 (enExample) |
| CA (1) | CA3216387A1 (enExample) |
| CL (1) | CL2023003114A1 (enExample) |
| CO (1) | CO2023015498A2 (enExample) |
| DK (1) | DK4114465T5 (enExample) |
| ES (1) | ES2963757T3 (enExample) |
| FI (1) | FI4114465T3 (enExample) |
| HR (1) | HRP20231255T1 (enExample) |
| HU (1) | HUE063562T2 (enExample) |
| IL (1) | IL307748A (enExample) |
| LT (1) | LT4114465T (enExample) |
| MX (1) | MX2023012465A (enExample) |
| PL (1) | PL4114465T3 (enExample) |
| PT (1) | PT4114465T (enExample) |
| RS (1) | RS64821B1 (enExample) |
| SI (1) | SI4114465T1 (enExample) |
| SM (1) | SMT202300382T1 (enExample) |
| TW (1) | TW202317182A (enExample) |
| WO (1) | WO2022223714A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1781705B1 (en) * | 2004-06-21 | 2014-10-08 | Medarex, L.L.C. | Interferon alpha receptor i antibodies and their uses |
| US20250002590A1 (en) * | 2021-04-23 | 2025-01-02 | Astrazeneca Ab | Treatment of lupus nephritis with anti-type i inf receptor antibody anifrolumab |
| LT4114465T (lt) | 2021-04-23 | 2023-11-10 | Astrazeneca Ab | Anti-ifnar1 dozavimo režimas, skirtas poodinei injekcijai |
| CN113621063A (zh) * | 2021-08-02 | 2021-11-09 | 江苏荃信生物医药有限公司 | 降低单克隆抗体生产中宿主细胞蛋白含量的亲和纯化方法 |
| CN121127499A (zh) | 2023-05-19 | 2025-12-12 | 阿斯利康(瑞典)有限公司 | 狼疮的治疗 |
| WO2025022280A1 (en) | 2023-07-21 | 2025-01-30 | Astrazeneca Ab | Treatment of neurodegenerative diseases |
| GB202315831D0 (en) | 2023-10-16 | 2023-11-29 | Astrazeneca Ab | Treatment of skin disease |
| GB202402824D0 (en) | 2024-02-28 | 2024-04-10 | Astrazeneca Ab | Treatment of chronic kidney disease |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2002250236A1 (en) | 2001-03-02 | 2002-09-19 | Medimmune, Inc. | Cd2 antagonists for treatment of autoimmune or inflammatory disease |
| US20040037809A1 (en) | 2002-06-28 | 2004-02-26 | Nastech Pharmaceutical Company Inc. | Compositions and methods for enhanced mucosal delivery of interferon beta |
| DK1711207T3 (da) | 2003-12-10 | 2013-03-11 | Medarex Inc | Interferon-alpha-antistoffer og anvendelse heraf |
| EP1781705B1 (en) * | 2004-06-21 | 2014-10-08 | Medarex, L.L.C. | Interferon alpha receptor i antibodies and their uses |
| WO2006138275A2 (en) | 2005-06-13 | 2006-12-28 | The Regents Of The University Of Michigan | Compositions and methods for treating and diagnosing cancer |
| WO2008093166A2 (en) | 2006-05-11 | 2008-08-07 | Ghent University | Sialoadhesin-related compositions and methods |
| WO2008070135A2 (en) | 2006-12-06 | 2008-06-12 | Medimmune, Llc. | Methods of treating systemic lupus erythematosus |
| ES2542836T3 (es) | 2007-07-12 | 2015-08-12 | The Brigham And Women's Hospital, Inc. | Composiciones y métodos para diagnosticar y evaluar miopatías inflamatorias |
| CN101909444B (zh) | 2007-11-05 | 2013-09-18 | 米迪缪尼有限公司 | 硬皮病治疗方法 |
| HUE028958T2 (en) | 2008-02-08 | 2017-01-30 | Medimmune Llc | Anti-ifnar1 antibodies with reduced fc ligand affinity |
| US20110287022A1 (en) | 2008-06-20 | 2011-11-24 | Medlmmune, Llc | Interferon alpha-induced pharmacodynamic markers |
| BRPI0917871A2 (pt) | 2008-08-15 | 2017-06-20 | Merrimack Pharmaceuticals Inc | agente terapêutico anti-erbb3 para uso em terapia de um tumor, métodos para predizer responsividade de um tumor de um agente terapêutco anti-erbb3, para selecionar terapia anti-erbb3 para um paciente, para predizer a resposta de células ao tratamento com um agente terapêutico, para identificar um biomarcador, e para evitar administração de uma droga para câncer anti-erbb3, e, kit para predizer a resposta das células ao tratamento com um agente terapêutico |
| ES2613055T3 (es) | 2009-09-03 | 2017-05-22 | Medimmune, Llc | Diagnóstico de interferón de tipo 1 |
| US9493570B2 (en) * | 2012-06-13 | 2016-11-15 | Medimmune, Llc | Fixed dosage regimens for anti-type I interferon receptor (IFNAR) antibodies |
| RS64263B1 (sr) * | 2015-08-19 | 2023-07-31 | Astrazeneca Ab | Stabilna anti-ifnar1 formulacija |
| CN106243226B (zh) | 2016-08-05 | 2019-02-12 | 北京智仁美博生物科技有限公司 | 抗人ifnar1的抗体及其用途 |
| US11059897B2 (en) * | 2018-09-18 | 2021-07-13 | I-Mab Biopharma Us Limited | Anti-IFNAR1 antibodies for treating autoimmune diseases |
| KR20210131354A (ko) * | 2019-02-15 | 2021-11-02 | 아스트라제네카 아베 | I형 인터페론-매개 장애 |
| KR102766960B1 (ko) | 2019-11-11 | 2025-02-11 | 아스트라제네카 아베 | 전신성 홍반성 루푸스에서 i형 인터페론 억제 |
| AU2021279277A1 (en) | 2020-05-29 | 2023-02-02 | Astrazeneca Ab | Treatment of cardiometabolic disease with inhibitors of type I interferon signalling |
| TW202237647A (zh) | 2020-10-08 | 2022-10-01 | 瑞典商阿斯特捷利康公司 | 狼瘡發作之治療 |
| US20240327529A1 (en) | 2020-11-18 | 2024-10-03 | Astrazeneca Ab | Steroid sparing |
| LT4114465T (lt) | 2021-04-23 | 2023-11-10 | Astrazeneca Ab | Anti-ifnar1 dozavimo režimas, skirtas poodinei injekcijai |
| US20250002590A1 (en) | 2021-04-23 | 2025-01-02 | Astrazeneca Ab | Treatment of lupus nephritis with anti-type i inf receptor antibody anifrolumab |
| CN113278070B (zh) | 2021-04-25 | 2022-06-14 | 福州迈新生物技术开发有限公司 | 抗ck17蛋白单克隆抗体及其细胞株、制备方法和应用 |
| CN113521276B (zh) * | 2021-07-13 | 2022-04-12 | 江苏荃信生物医药股份有限公司 | 包含抗人干扰素α受体1(IFNAR1)单克隆抗体的液体制剂 |
-
2022
- 2022-04-21 LT LTEPPCT/EP2022/060592T patent/LT4114465T/lt unknown
- 2022-04-21 KR KR1020257019825A patent/KR20250092298A/ko active Pending
- 2022-04-21 PL PL22724683.2T patent/PL4114465T3/pl unknown
- 2022-04-21 AU AU2022260531A patent/AU2022260531B2/en active Active
- 2022-04-21 CN CN202411936092.4A patent/CN120392997A/zh active Pending
- 2022-04-21 WO PCT/EP2022/060592 patent/WO2022223714A1/en not_active Ceased
- 2022-04-21 ES ES22724683T patent/ES2963757T3/es active Active
- 2022-04-21 CA CA3216387A patent/CA3216387A1/en active Pending
- 2022-04-21 KR KR1020237039588A patent/KR20230166134A/ko not_active Ceased
- 2022-04-21 IL IL307748A patent/IL307748A/en unknown
- 2022-04-21 FI FIEP22724683.2T patent/FI4114465T3/fi active
- 2022-04-21 PT PT227246832T patent/PT4114465T/pt unknown
- 2022-04-21 EP EP23186947.0A patent/EP4306541A3/en active Pending
- 2022-04-21 HR HRP20231255TT patent/HRP20231255T1/hr unknown
- 2022-04-21 BR BR112023021761A patent/BR112023021761A2/pt unknown
- 2022-04-21 EP EP22724683.2A patent/EP4114465B1/en active Active
- 2022-04-21 HU HUE22724683A patent/HUE063562T2/hu unknown
- 2022-04-21 SM SM20230382T patent/SMT202300382T1/it unknown
- 2022-04-21 JP JP2023562678A patent/JP7484027B2/ja active Active
- 2022-04-21 MX MX2023012465A patent/MX2023012465A/es unknown
- 2022-04-21 SI SI202230007T patent/SI4114465T1/sl unknown
- 2022-04-21 RS RS20230991A patent/RS64821B1/sr unknown
- 2022-04-21 CN CN202411940557.3A patent/CN120514844A/zh active Pending
- 2022-04-21 DK DK22724683.2T patent/DK4114465T5/da active
- 2022-04-22 TW TW111115445A patent/TW202317182A/zh unknown
- 2022-04-22 US US17/660,317 patent/US20220340669A1/en not_active Abandoned
-
2023
- 2023-04-21 US US18/305,235 patent/US12060429B2/en active Active
- 2023-10-19 CL CL2023003114A patent/CL2023003114A1/es unknown
- 2023-11-16 CO CONC2023/0015498A patent/CO2023015498A2/es unknown
-
2024
- 2024-02-27 US US18/589,200 patent/US20240360231A1/en active Pending
- 2024-03-18 AU AU2024201743A patent/AU2024201743A1/en active Pending
- 2024-05-01 JP JP2024074264A patent/JP2024102205A/ja active Pending
- 2024-05-15 US US18/665,297 patent/US20240400699A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024102205A5 (enExample) | ||
| US20020131955A1 (en) | Interleukin antagonists for the treatment of neurological, retinal and muscular disorders | |
| US6471961B1 (en) | Interleukin antagonists for the treatment of neurological, retinal and muscular disorders | |
| ES2963757T3 (es) | Régimen de dosificación de anti-ifnar1 para inyección subcutánea | |
| CN109963577B (zh) | 用于通过施用il-4r抑制剂治疗严重特应性皮炎的方法 | |
| KR20210010518A (ko) | Il-4r 억제제를 투여하여 아토피성 피부염을 치료하는 방법 | |
| JP2022160685A5 (enExample) | ||
| JP2021130668A (ja) | 多発性骨髄腫（ｍｍ）の処置 | |
| JP2015533806A (ja) | 関節リウマチの治療 | |
| EP0303687B1 (en) | Compositions for enhancing adcc therapy | |
| Pitarokoili et al. | Anti-inflammatory and immunomodulatory potential of human immunoglobulin applied intrathecally in Lewis rat experimental autoimmune neuritis | |
| CA3176574A1 (en) | Ofatumumab for treating ms while maintaining serum igg | |
| WO2017221174A1 (en) | Methods of treating vitiligo using interleukin-17 (il-17) antibodies | |
| JP2022523530A (ja) | 化膿性汗腺炎の治療のための抗ＩＬ－α抗体 | |
| EP4612183A1 (en) | Methods for treating hand and foot dermatitis by administering an il-4r antagonist | |
| JP3973360B2 (ja) | 関節リウマチまたは皮膚疾患の処置に使用するためのｃｄ２５結合分子 | |
| CN115515978A (zh) | 用于治疗呼吸系统疾病的pan-elr+cxc趋化因子抗体 | |
| WO2021018191A1 (zh) | Il-17拮抗剂治疗自身免疫疾病的方法 | |
| KR20250029297A (ko) | 화농성 한선염 치료를 위한 범-elr+ cxc 케모카인 항체 | |
| MacLean et al. | Immunologic therapy for relapsing-remitting multiple sclerosis | |
| Sorbera et al. | Adalimumab | |
| JPWO2019186369A5 (enExample) | ||
| TADA et al. | New Therapy in Rheumatoid Arthritis˜ Biological DMARDs and JAK Inhibitors˜ | |
| RU2801204C2 (ru) | Способ лечения атопического дерматита посредством введения ингибитора ил-4r | |
| Croasdell | 35th congress of the European committee for treatment and research in multiple sclerosis (ECTRIMS) |